We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03062358
Recruitment Status : Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : March 4, 2022
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 30, 2021
Estimated Study Completion Date : June 30, 2023
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 7, 2022